JP2022510690A5 - - Google Patents
Info
- Publication number
- JP2022510690A5 JP2022510690A5 JP2021532071A JP2021532071A JP2022510690A5 JP 2022510690 A5 JP2022510690 A5 JP 2022510690A5 JP 2021532071 A JP2021532071 A JP 2021532071A JP 2021532071 A JP2021532071 A JP 2021532071A JP 2022510690 A5 JP2022510690 A5 JP 2022510690A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024199809A JP2025028061A (ja) | 2018-12-05 | 2024-11-15 | 肝障害の処置のための組成物及び方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862775799P | 2018-12-05 | 2018-12-05 | |
| US62/775,799 | 2018-12-05 | ||
| US201962821303P | 2019-03-20 | 2019-03-20 | |
| US62/821,303 | 2019-03-20 | ||
| PCT/US2019/064548 WO2020117987A1 (en) | 2018-12-05 | 2019-12-04 | Compositions and methods for the treatment of liver disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024199809A Division JP2025028061A (ja) | 2018-12-05 | 2024-11-15 | 肝障害の処置のための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022510690A JP2022510690A (ja) | 2022-01-27 |
| JP2022510690A5 true JP2022510690A5 (https=) | 2022-12-13 |
| JPWO2020117987A5 JPWO2020117987A5 (https=) | 2022-12-13 |
Family
ID=70974003
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021532071A Pending JP2022510690A (ja) | 2018-12-05 | 2019-12-04 | 肝障害の処置のための組成物及び方法 |
| JP2024199809A Pending JP2025028061A (ja) | 2018-12-05 | 2024-11-15 | 肝障害の処置のための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024199809A Pending JP2025028061A (ja) | 2018-12-05 | 2024-11-15 | 肝障害の処置のための組成物及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220016136A1 (https=) |
| EP (1) | EP3890748A4 (https=) |
| JP (2) | JP2022510690A (https=) |
| KR (1) | KR20210099612A (https=) |
| CN (1) | CN113365637A (https=) |
| AU (2) | AU2019394947B2 (https=) |
| BR (1) | BR112021010916A2 (https=) |
| CA (1) | CA3121620A1 (https=) |
| MX (5) | MX2021006575A (https=) |
| WO (1) | WO2020117987A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006128058A2 (en) | 2005-05-26 | 2006-11-30 | Metabasis Therapeutics, Inc. | Thyromimetics for the treatment of fatty liver diseases |
| CA3044059A1 (en) | 2016-11-21 | 2018-05-24 | Viking Therapeutics, Inc. | Method of treating glycogen storage disease |
| US11707472B2 (en) | 2017-06-05 | 2023-07-25 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
| ES3053674T3 (en) | 2018-03-22 | 2026-01-23 | Viking Therapeutics Inc | Crystalline forms and methods of producing crystalline forms of a compound |
| WO2020117962A1 (en) | 2018-12-05 | 2020-06-11 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
| CN112707892A (zh) * | 2019-10-24 | 2021-04-27 | 苏州泽璟生物制药股份有限公司 | 哒嗪酮或哒嗪类化合物及其衍生物和药物组合物 |
| CN119841865A (zh) | 2020-02-07 | 2025-04-18 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| US11752161B2 (en) | 2020-03-27 | 2023-09-12 | Gannex Pharma Co., Ltd. | Pharmaceutical compositions, method of making and method of using thereof |
| FI4143183T3 (fi) | 2020-04-29 | 2026-01-07 | Gasherbrum Bio Inc | Heterosyklisiä glp-1-agonisteja |
| WO2021252392A1 (en) * | 2020-06-09 | 2021-12-16 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of liver disorders |
| WO2021259309A1 (zh) * | 2020-06-24 | 2021-12-30 | 广州市恒诺康医药科技有限公司 | Glp-1受体激动剂及其药物组合物和用途 |
| CN115093404B (zh) * | 2020-07-17 | 2024-06-21 | 瀚海新拓(杭州)生物医药有限公司 | 苯并五元杂环磺酰胺类化合物、其制备方法、药物组合物及应用 |
| PE20231181A1 (es) | 2020-08-06 | 2023-08-11 | Gasherbrum Bio Inc | Agonistas del glp-1 heterociclicos |
| KR20240068737A (ko) | 2021-09-27 | 2024-05-17 | 테른스 파마슈티칼스, 인크. | Glp-1r 효능제로서의 벤즈이미다졸 카복실산 |
| CN119137124A (zh) | 2022-03-09 | 2024-12-13 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| WO2023198140A1 (en) | 2022-04-14 | 2023-10-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| JP2026501171A (ja) | 2022-12-15 | 2026-01-14 | ガシャーブラム・バイオ・インコーポレイテッド | Ｇｌｐ－１アゴニスト活性を有する化合物の塩および固体形態 |
| US20240398794A1 (en) | 2023-04-07 | 2024-12-05 | Terns Pharmaceuticals, Inc. | COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOF |
| WO2025193816A1 (en) * | 2024-03-14 | 2025-09-18 | Viking Therapeutics, Inc. | Pharmaceutical compositions and methods for the treatment of metabolic and liver disorders |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006128058A2 (en) * | 2005-05-26 | 2006-11-30 | Metabasis Therapeutics, Inc. | Thyromimetics for the treatment of fatty liver diseases |
| CN1882327A (zh) * | 2003-11-19 | 2006-12-20 | 症变治疗公司 | 含磷的新的拟甲状腺素药 |
| EA024697B1 (ru) * | 2009-04-27 | 2016-10-31 | Иммурон Лимитед | Применение композиции, содержащей обогащенный анти-lps-антителами иммуноглобулиновый препарат, для лечения заболеваний печени |
| WO2011038207A1 (en) * | 2009-09-25 | 2011-03-31 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyroid hormone receptor agonists and methods of use |
| EP3438087A1 (en) * | 2012-05-02 | 2019-02-06 | Boehringer Ingelheim International GmbH | Substituted 3-haloallylamine inhibitors of ssao and uses thereof |
| CN110536682B (zh) * | 2017-04-18 | 2023-01-06 | 基恩菲特公司 | 依拉非诺或其衍生物与抗nash、抗纤维化或抗胆汁淤积药剂的组合 |
| US11707472B2 (en) * | 2017-06-05 | 2023-07-25 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
| WO2021252392A1 (en) * | 2020-06-09 | 2021-12-16 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of liver disorders |
-
2019
- 2019-12-04 EP EP19893549.6A patent/EP3890748A4/en active Pending
- 2019-12-04 BR BR112021010916-1A patent/BR112021010916A2/pt unknown
- 2019-12-04 CA CA3121620A patent/CA3121620A1/en active Pending
- 2019-12-04 CN CN201980091024.3A patent/CN113365637A/zh active Pending
- 2019-12-04 US US17/311,014 patent/US20220016136A1/en active Pending
- 2019-12-04 WO PCT/US2019/064548 patent/WO2020117987A1/en not_active Ceased
- 2019-12-04 MX MX2021006575A patent/MX2021006575A/es unknown
- 2019-12-04 KR KR1020217020331A patent/KR20210099612A/ko active Pending
- 2019-12-04 JP JP2021532071A patent/JP2022510690A/ja active Pending
- 2019-12-04 AU AU2019394947A patent/AU2019394947B2/en active Active
-
2021
- 2021-06-03 MX MX2024001203A patent/MX2024001203A/es unknown
- 2021-06-03 MX MX2024001205A patent/MX2024001205A/es unknown
- 2021-06-03 MX MX2024001201A patent/MX2024001201A/es unknown
- 2021-06-03 MX MX2024001204A patent/MX2024001204A/es unknown
-
2024
- 2024-11-15 JP JP2024199809A patent/JP2025028061A/ja active Pending
-
2025
- 2025-08-22 AU AU2025220854A patent/AU2025220854A1/en active Pending